Literature DB >> 19580428

MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer.

Pankaj Taneja1, Donna P Frazier, Robert D Kendig, Dejan Maglic, Takayuki Sugiyama, Fumitake Kai, Neetu K Taneja, Kazushi Inoue.   

Abstract

Mouse mammary tumor virus (MMTV) long terminal repeat (LTR)-driven transgenic mice are excellent models for breast cancer as they allow for the targeted expression of various oncogenes and growth factors in neoplastic transformation of mammary glands. Numerous MMTV-LTR-driven transgenic mouse models of breast cancer have been created in the past three decades, including MMTV-neu/ErbB2, cyclin D1, cyclin E, Ras, Myc, int-1 and c-rel. These transgenic mice develop mammary tumors with different latency, histology and invasiveness, reflecting the oncogenic pathways activated by the transgene. Recently, homologous sequences of the env gene of MMTV have been identified in approximately 40% of human breast cancers, but not in normal breast or other types of cancers, suggesting possible involvement of mammary tumor virus in human breast carcinogenesis. Accumulating evidence demonstrates the association of MMTV provirus with progesterone receptor, p53 mutations and advanced-stage breast cancer. Thus, the detection of MMTV-like sequences may have diagnostic value to predict the clinical outcome of breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19580428      PMCID: PMC2759974          DOI: 10.1586/erm.09.31

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  150 in total

1.  Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas.

Authors:  K Inoue; F Zindy; D H Randle; J E Rehg; C J Sherr
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

2.  CDC6 interacts with c-Myc to inhibit E-box-dependent transcription by abrogating c-Myc/Max complex.

Authors:  M Takayama; T Taira; S M Iguchi-Ariga; H Ariga
Journal:  FEBS Lett       Date:  2000-07-14       Impact factor: 4.124

3.  A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas.

Authors:  T D Bui; J Rankin; K Smith; E L Huguet; S Ruben; T Strachan; A L Harris; S Lindsay
Journal:  Oncogene       Date:  1997-03-13       Impact factor: 9.867

4.  Progression from normal breast pathology to breast cancer is associated with increasing prevalence of mouse mammary tumor virus-like sequences in men and women.

Authors:  Caroline E Ford; Margaret Faedo; Roger Crouch; James S Lawson; William D Rawlinson
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

5.  Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis.

Authors:  Nathalie Dourdin; Babette Schade; Robert Lesurf; Michael Hallett; Robert J Munn; Robert D Cardiff; William J Muller
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

6.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome.

Authors:  R Nusse; H E Varmus
Journal:  Cell       Date:  1982-11       Impact factor: 41.582

7.  7,12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB.

Authors:  Sangmin Ryan Shin; Nuria Sánchez-Velar; David H Sherr; Gail E Sonenshein
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

8.  Cyclin E, a potential prognostic marker for breast cancer.

Authors:  K Keyomarsi; N O'Leary; G Molnar; E Lees; H J Fingert; A B Pardee
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

9.  Antibodies reactive with murine mammary tumor virus in sera of patients with breast cancer: geographic and family studies.

Authors:  N K Day; S S Witkin; N H Sarkar; D Kinne; D J Jussawalla; A Levin; C C Hsia; N Geller; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

Review 10.  The possible involvement of virus in breast cancer.

Authors:  Marla Karine Amarante; Maria Angelica Ehara Watanabe
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-14       Impact factor: 4.553

View more
  35 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

Review 2.  Infection, stem cells and cancer signals.

Authors:  S Sell
Journal:  Curr Pharm Biotechnol       Date:  2011-02-01       Impact factor: 2.837

3.  Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells.

Authors:  Hannah Schmucker; Walker M Blanding; Julia M Mook; Jessica F Wade; Jang Pyo Park; Kerri Kwist; Hiral Shah; Brian W Booth
Journal:  Cell Oncol (Dordr)       Date:  2017-11-27       Impact factor: 6.730

4.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

Review 5.  Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Int J Cancer       Date:  2016-09-12       Impact factor: 7.396

6.  Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases.

Authors:  Jianqiang Bao; Alessandra Di Lorenzo; Kevin Lin; Yue Lu; Yi Zhong; Manu M Sebastian; William J Muller; Yanzhong Yang; Mark T Bedford
Journal:  Cancer Res       Date:  2018-10-23       Impact factor: 12.701

7.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

8.  DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer.

Authors:  Dejan Maglic; Daniel B Stovall; J Mark Cline; Elizabeth A Fry; Ali Mallakin; Pankaj Taneja; David L Caudell; Mark C Willingham; Guangchao Sui; Kazushi Inoue
Journal:  J Pathol       Date:  2015-02-09       Impact factor: 7.996

9.  Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.

Authors:  Adrián Blanco-Gómez; Lourdes Hontecillas-Prieto; Roberto Corchado-Cobos; Natalia García-Sancha; Jesús Pérez-Losada; Sonia Castillo-Lluva; Nélida Salvador; Andrés Castellanos-Martín; María Del Mar Sáez-Freire; Marina Mendiburu-Eliçabe; Diego Alonso-López; Javier De Las Rivas; Mar Lorente; Ana García-Casas; Sofía Del Carmen; María Del Mar Abad-Hernández; Juan Jesús Cruz-Hernández; César Augusto Rodríguez-Sánchez; Juncal Claros-Ampuero; Begoña García-Cenador; Javier García-Criado; Akira Orimo; Thomas Gridley
Journal:  Cancer Res       Date:  2020-10-06       Impact factor: 12.701

Review 10.  Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.